Navigation Links
Athena Diagnostics Announces New Genetic Testing Services for Rare Neurological Disorders

WORCESTER, Mass. and MADISON, N.J., March 18, 2013 /PRNewswire/ -- Athena Diagnostics, a leader in neurological diagnostics, today announced the clinical availability of new genetic tests to aid the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy and certain movement disorders. The lab-developed tests are available through Athena Diagnostics, a business of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. 

The tests will be unveiled during the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 (Booth 1413).

The tests streamline the diagnostic process by using gene sequencing and bioinformatics to evaluate many clinically-relevant genes with a single blood draw. Test reports provide information to assist clinicians and genetic counselors in confirming a diagnosis, developing a targeted treatment plan and managing patient care.

The new services include expanded testing for Charcot-Marie-Tooth disease (CMT), a hereditary motor sensory neuropathy for which early accurate diagnosis is critical to ensure patients avoid contra-indicated medications which can worsen symptoms. They also include DNA sequencing tests for myofibrillar myopathy (MFM), a debilitating disease that can lead to cardiac and respiratory complications, but is often confused with CMT and other conditions. Athena provides a broad diagnostic menu for MFM that may help physicians identify the disorder, hastening the use of aggressive supportive care that may maximize functional activity and prolong life expectancy. 

In addition, the company is offering new tests for hereditary sensory and autonomic neuropathy (HSAN), hereditary neuralgic amyotrophy (HNA), hypokalemic periodic paralysis (HOKPP), limb girdle muscular dystrophy (LGMD), benign familiar infantile epilepsy and familial paroxysmal kinesigenic dyskinesia (FPKD).

Athena Diagnostics' clinical laboratory in Worcester, Mass. developed, validated and now offers the new tests.

"The genetic causes of neurological disorders are sometimes difficult to diagnose without reliable tests that are guided by specific clinical phenotypes," said Joseph J. Higgins , MD, FAAN, medical director for Quest Diagnostics Neurology and Athena Diagnostics. "In addition, overlapping clinical signs and symptoms in certain rare, neurogenetic disorders present a different challenge for physicians. The new test services for evaluating epilepsy and neuromuscular disorders will aid physicians in diagnosing these diseases, some of which may be amenable to treatment, and assist in the diagnosis of other potentially affected family members. The results will also better prepare patients and their families to make informed life decisions based on their health risks." 

In addition, scientists from Athena Diagnostics with report new research findings during the conference. The presentations include results of a study with experts from Penn State College of Medicine on the relative prevalence of subtypes of limb girdle muscular dystrophies (poster PO7.030). The study, based on nearly 500 test results, is believed to be the largest cohort of genetically confirmed LGMD cases.  

The new tests and research build on Athena's leadership in diagnostic information services for rare and esoteric disorders. Athena Diagnostics was the first laboratory company to offer a clinically validated C9orf72 genetic test to aid in the diagnosis of familial and sporadic amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig 's disease. 

Athena Diagnostics is also a leader in genetic testing services for dementia, including Alzheimer's disease. Quest Diagnostics today unveiled a neurology test panel for aiding the detection of secondary causes of dementia. Medical experts at Athena Diagnostics advised Quest's scientists on the panel's concept.

Information about the new panel will also be available at AAN.

About Athena Diagnostics
Athena Diagnostics is a leader in diagnostic testing for neurological diseases and offers innovative tests for Alzheimer's disease, muscular dystrophy and other neuromuscular and developmental disorders. Athena, a division of Quest Diagnostics, is dedicated to providing neurologists and other physicians and specialists with insights that can improve patient health.   Athena provides the most comprehensive test menu and intellectual property portfolio for neurological, endocrine, and renal conditions through more than 400 diagnostic tests. For more information, visit

About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at or follow us at Diagnostics and

Quest, Quest Diagnostics, Athena Diagnostics and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics.

Quest Diagnostics Contacts:
Wendy Bost (Media): 973-520-2800
Dan Haemmerle (Investors): 973-520-2900

SOURCE Athena Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Enters Multi Year Contractual Relationship With Major Bangladesh Pharmaceutical Manufacturer
2. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
3. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
4. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
5. Ariosa Diagnostics Introduces Y-Chromosome Analysis Test Option
6. PET/MR Scanner Holds Promise For Expanded Diagnostics
7. In Vitro Diagnostics Markets Grow at Double the Pace of Pharma Markets in Shift toward Globalization
8. MGC Diagnostics Corporation Reports 2013 First Fiscal Quarter Operating Results
9. MD Buylines User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
10. MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP
11. MGC Diagnostics Corporation to Report First Quarter Fiscal 2013 Financial Results on Tuesday, March 5, 2013
Post Your Comments:
(Date:11/25/2015)... 2015 Endo International plc (NASDAQ: ENDP ) ... President and CEO, will discuss corporate updates at the 27 ... New York on Wednesday, December 2, 2015 at ... Investor Relations, and then the link to the event. Participants ... time to visit the site and download any streaming media ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... in both surgical and non-surgical treatments, announced the expansion of his private practice ... Surgery. , Highly trained and nationally recognized for his natural approach, Dr. ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract ... significant expansion of its current state of the art research, development and manufacturing ... to increase its manufacturing capacity as well as to support its clients’ growing ...
Breaking Medicine News(10 mins):